June 2, 2020

First Case of Drug‐induced Liver Injury Associated with the Use of Tocilizumab in a Patient with COVID‐19

Category: Article Summary

Topic: Testing and Treatment

• [pre-print, not peer reviewed] Muhovic et al. present a case of probable drug-induced liver injury in a patient with severe COVID-19 who received tocilizumab. One day after receiving the drug, which functions as an inhibitor of interleukin-6, acute liver injury was verified in laboratory analyses. Biopsy to diagnose drug-induced liver injury was not performed due to the patient’s fragile condition. The authors suggest the need to liver function monitoring among COVID-19 patients receiving potentially hepatotoxic drugs.  

Muhović et al. (May 17, 2020). First Case of Drug‐induced Liver Injury Associated with the Use of Tocilizumab in a Patient with COVID‐19. Liver International. https://doi.org/10.1111/liv.14516